Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)
TipRanks (Thu, 28-Mar 1:30 PM ET)
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
Globe Newswire (Thu, 21-Mar 7:00 AM ET)
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Thu, 14-Mar 8:00 AM ET)
Globe Newswire (Mon, 12-Feb 7:00 AM ET)
MediWound to Participate in Two Upcoming Investor Conferences
Globe Newswire (Mon, 5-Feb 8:00 AM ET)
Globe Newswire (Tue, 9-Jan 7:00 AM ET)
Globe Newswire (Thu, 28-Dec 7:00 AM ET)
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Mediwound Ltd. - trades on the NASDAQ stock market under the symbol MDWD.
As of March 28, 2024, MDWD stock price declined to $14.25 with 175,147 million shares trading.
MDWD has a beta of 0.53, meaning it tends to be less sensitive to market movements. MDWD has a correlation of 0.01 to the broad based SPY ETF.
MDWD has a market cap of $135.26 million. This is considered a Micro Cap stock.
Last quarter Mediwound Ltd. - reported $5 million in Revenue and -$.19 earnings per share. This beat revenue expectation by $18,000 and exceeded earnings estimates by $.04.
In the last 3 years, MDWD stock traded as high as $43.54 and as low as $7.10.
The top ETF exchange traded funds that MDWD belongs to (by Net Assets): IWC.
MDWD has underperformed the market in the last year with a price return of +14.0% while the SPY ETF gained +33.6%. However, in the short term, MDWD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +38.5% vs +10.1% return in SPY. But in the last 2 weeks, MDWD shares have been beat by the market, returning -6.3% compared to an SPY return of +1.7%.
MDWD support price is $14.47 and resistance is $15.73 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDWD stock will trade within this expected range on the day.